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ARTICLE OPEN
Prevalence of inappropriate prescribing of inhaled
corticosteroids for respiratory tract infections in the
Netherlands: a retrospective cohort study
Martina Teichert1,2, Tjard Schermer3, Lotte van den Nieuwenhof3, Peter AGM De Smet1,4 and Michel Wensing1
BACKGROUND: Inhaled corticosteroids (ICS) are recommended in prevailing guidelines for use in patients with persistent asthma
or moderate-to-severe chronic obstructive pulmonary disease (COPD) and recurrent exacerbations. Recent data from Australia
showed that 44% of patients with a single ICS dispensing and without other respiratory inhalation medications (‘one-off ICS’) were
co-dispensed oral antibiotics. Evidence of the merit of ICS for treating respiratory infections in subjects without asthma or COPD is
lacking.
AIMS: The aims of the study were to describe the rate of one-off ICS dispensing in combination with oral antibiotics in subjects
without chronic respiratory conditions in the Netherlands, and to compare this with the rate of one-off ICS dispensing in
combination with oral antibiotics as reported earlier from Australia.
METHODS: Dispensing data were obtained from the Dutch Foundation of Pharmaceutical Statistics. Additional information was
available on patients’ age, sex and prescriber. Patients with any ICS dispensing in 2011 were selected.
RESULTS: Data were available from 1,725 Dutch community pharmacies (88%). Of 845,068 ICS users in 2011, 10% were dispensed
one-off ICS, among which 13% had oral antibiotics co-dispensed. These ICS were mainly prescribed by general practitioners,
mostly during winter months, for elderly persons, after high dosages of oral corticosteroids, and in single-inhaler combinations with
a long-acting β2-agonist. The extrapolated total annual expense for this ICS use was € 555,000.
CONCLUSION: In the Netherlands one-off ICS dispensing in combination with oral antibiotics in subjects without chronic
respiratory conditions was considerably lower than in Australia.
npj Primary Care Respiratory Medicine (2014) 24, 14086; doi:10.1038/npjpcrm.2014.86; published online 16 October 2014
INTRODUCTION
Inhaled corticosteroids (ICS) have pronounced anti-inﬂammatory
properties.1 They are therefore effective in reducing morbidity and
mortality in patients with persistent asthma2–4 and in diminishing
the incidence of exacerbations in patients with chronic obstructive
pulmonary disease (COPD).5–7 Besides these beneﬁts, ICS use
can cause adverse effects like oropharyngeal candidiasis, easy
bruisability, cataract, open-angle glaucoma and lowering of spine
and femur bone densities.6,7 Furthermore, ICS use is associated
with an increased risk of pneumonia, possibly due to protracted
symptomatic exacerbations.8,9
In the prevailing guidelines for asthma and COPD, the evidence
of the effectiveness of ICS use has been weighted critically, and for
their use outside these recommendations the risk of side effects
does not outweigh the beneﬁts.10–13 In national and international
guidelines for asthma, ICS are recommended as preventive
medication for daily use to improve disease control in addition to
bronchodilators.10–14 Pharmacotherapy for patients with COPD is
mainly based on bronchodilators, and ICS are only advised in
patients with moderate-to-very severe COPD with a high risk of
exacerbations.11,13
In the Netherlands the use of inhalation medication increased
by 7% from 2007 to 2012.15 In 2012, the combination of
salmeterol and ﬂuticasone ranked ﬁrst on the list of annual costs
of reimbursed drugs (€ 118 million), and the combination of
formoterol with budesonide was ranked third (€ 94 million).16 It is,
however, questionable whether all ICS prescribing is consistent
with the prevailing guidelines. Inappropriate prescribing practices
have previously been reported: a Dutch study concluded from a
questionnaire administered to general practitioners (GPs) that
30% of asthma and/or COPD patients who used ICS did not have a
clear indication for this treatment.17 In a study from the United
Kingdom it was seen that 25% of COPD patients received ICS,
which was not consistent with the recently published GOLD
guidelines.18 Another study from the United Kingdom found 43%
overtreatment with ICS in COPD patients,1 and a Spanish study
reported inappropriate ICS use in 18% of COPD patients.19
A recent Australian study showed that 44% of patients with a
single ICS dispensing and without other respiratory inhalation
medication were co-dispensed oral antibiotics, indicating
inappropriate prescribing of ICS for respiratory tract infections.20
The rate of inappropriate ICS prescribing for the management of
symptoms of respiratory infections in subjects without an under-
lying chronic respiratory condition has not been studied yet in the
Netherlands. With data from a national outpatient dispensing
database we compared the rate of ICS use without any other
respiratory medication in the 12 months before or after a single
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ICS dispensing and in combination with antibiotics in the
Netherlands with the results from Australia20 and we analysed
possible determinants for this.
MATERIALS AND METHODS
Study design
We performed a retrospective observational study to evaluate ICS
dispensing within routinely collected dispensing data from Dutch
community pharmacies.
Data source
Routinely collected data were extracted from the Dutch Foundation of
Pharmaceutical Statistics (SFK). This database has been used before in drug
utilisation studies.21,22 SFK collects dispensing data from 95% of the total
1,981 Dutch community pharmacies.23 SFK data provide detailed informa-
tion on the drugs dispensed, including the codes from the ATC system,24
the prescribed daily dose and wholesaler’s price. Information on patients’
sex and year of birth was also available. The data do not contain any
information on dispensings from hospital pharmacies or clinical diagnoses.
Medication of a speciﬁc patient is tracked in the pharmacy over time by a
deﬁned unique code per patient. For the degree of urbanisation, the postal
code of the dispensing pharmacy was categorised in strata based on
the classiﬁcation of the Dutch Agency of Statistics.25 Information on
prescribers consisted of an anonymous code per prescriber and
information for being a GP or any medical specialist as far as this had
been recorded in the pharmacy. The advisory board of SFK approved the
study. For this study, data from all Dutch community pharmacies that had
provided complete data without changes in patient numbering for the
years 2010, 2011 and 2012 could be used.
Measures
Data were used from pharmacies that had delivered complete data for the
whole calendar year from 2010 to 2012. All patients with at least one ICS
dispensing during the calendar year 2011, either alone or in single-inhaler
combination with long-acting β2-agonist (LABA; ATC codes: R03BA,
R03AK06, R03AK07), were included in the study cohort. The calendar years
2010 and 2012 were used as prior and posterior measurement periods to
determine earlier and later dispensings for patients of the cohort. To
warrant complete data history for the patients included, patients were
excluded who—besides dispensing of a one-off ICS—did not have a
dispensing of any other medication in 2011 or 2012 (‘drop-in’ patients;
Figure 1). Within the total group of ICS users, patients who had their ﬁrst
dispensing of an ICS in 2011 without a previous ICS dispensing during the
preceding 12 months (‘ﬁrst ICS’) were identiﬁed. Next, only those patients
were selected who had no subsequent dispensing of an ICS in the following
12 months (‘single ICS’). Among these patients, those who had not received
any other respiratory medication (ATC codes R03, except R03AK06 or
R03AK07 or R03BA) in the 12 months prior to or after the single ICS
dispensing in 2011 were labelled as ‘one-off ICS’ users. For these patients
co-dispensing of antibiotics was deﬁned as dispensing an oral antibiotic
within the drug classes commonly used for respiratory tract infections,
comparable to the selection made by Poulos et al.20 in their paper
(tetracyclines, penicillines, sulphonamides in combination with trimetho-
prim, quinolones and combinations of these drugs; ATC-codes: J01A, J01C.
J01E, J01F, J01M, J01R), within 7 days prior or past of the date of one-off ICS
dispensing. As we did not consider information on the diagnosis, we only
selected dispensings of these antibiotics for a prescribed period of use
Number of patients with any ICS
dispensing in 2011 (‘ICS users’)
845,068
‘Drop-in’
patients
7
Number of patients without a ICS
dispensing 12 months before the ICS
dispensing in 2011 (‘first ICS’)
276,229
Number of patients without a ICS
dispensing 12 months before and
after the ICS dispensing in 2011
(‘single ICS’)
158,344
Single ICS with no other respiratory
medication within ±12 months
(‘one-off ICS’)
84,821
No Yes
Use of antiallergic
medication between
2010 and 2012?
One-off ICS without
antiallergics
49,965
One-off ICS with
antiallergics
34,856
Patients with antibiotic
dispensings <7 or >16 
days 16
Co-dispensed oral
antibiotics within ±7 days
of ICS dispensing
6,735
Co-dispensed oral
antibiotics within ±7 days
of ICS dispensing
4,210
Patients with antibiotic
dispensings <7 or >16
days 4
Figure 1. Cohort of one-off inhaled corticosteroids (ICS) users in combination with oral antibiotics (based on data from 1,725 (89% of all)
Dutch community pharmacies).
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between 7 and 15 days according to the Dutch GP recommendations of
antibiotic drug use for respiratory infections.26 Patients with a co-dispensed
antibiotic for a shorter or longer period of time were not labelled as having
‘concomitant antibiotic use’. Usage of a course of high-dose oral
corticosteroids was deﬁned as a dispensing with ATC codes H02AB06 or
H02AB07 in the 12 months prior to the one-off ICS dispensing. In order to
differentiate between subjects with and those without allergies, one-off ICS
users with antibiotics were stratiﬁed on the basis of having received or not
received any dispensing of antiallergic medication (R01AC, R01AD, R03BC,
R03DC, R03DX05, R06) between 2010 and 2012.
Data analysis
For one-off ICS users the proportion of those who were co-dispensed a
7–15-day course of oral antibiotics was calculated, stratiﬁed for use of
antiallergic medication. These proportions were grouped for the variables
sex, age group, type of prescriber of the one-off ICS, earlier oral
corticosteroid treatment and the urbanisation degree of the dispensing
pharmacy as potential determinants. The relationship of co-dispensing a
course of antibiotics in patients with a one-off ICS dispensing was
expressed in terms of odds ratios (ORs) using univariate logistic regression
for each of the potential confounders. Next, multivariate logistic regression
was used to estimate the inﬂuence of co-dispensed oral antibiotics on the
odds of receiving a one-off ICS dispensing within all users of ICS in 2011.
Using forward inclusion we obtained a ﬁnal model that contained only
confounders that changed the OR for antibiotic co-medication by more
than 10%. For one-off ICS users with co-dispensed oral antibiotics, the
timing of co-dispensing within 7 days before or after the ICS dispensing
was analysed. To describe seasonal patterns, the monthly incidence of co-
dispensing was displayed by age group, based on the age categories from
Table 1. Cohort characteristics of one-off ICSˆ users who were co-dispensed oral antibiotics in 2011a
Variable Subgroup without antiallergics between 2010 and 2012 Subgroup with antiallergics between 2010 and 2012
Proportion co-dispensed oral
antibiotics
Odds ratio (95% CI)b Proportion co-dispensed oral
antibiotics
Odds ratio (95% CI)b
Overall within 1,725
community pharmacies
6,735 Patients co-dispensed
antibiotics among 49,965 one-off
ICS users (13.5%)
4,210 Patients co-dispensed
antibiotics within 34,856 one-off ICS
users (12.1%)
Sex
Males 2,854 (13.4%) 1.0 1,539 (11.3%) 1.0
Females 3,881 (13.5%) 1.01 (0.95–1.06) 2,671 (12.6%) 1.14 (1.07–1.22)
Age group (years)c
0–6 339 (11,8%) 1.22 (1.03–1.44) 97 (12.1%) 1.61 (1.24–2.08)
7–16 295 ( 9.9%) 1 186 (7.9%) 1
17–39 1,060 (11.3%) 1.17 (1.02–1.34) 947 (10.4%) 1.36 (1.16–1.60)
40–64 2,945 (14.1%) 1.50 (1.32–1.71) 1,971 (12.5%) 1.67 (1.43–1.96)
65–79 1,578 (15.1%) 1.62 (1.42–1.85) 810 (14.7%) 2.02 (1.71–2.38)
≥ 80 518 (15.0%) 1.61 (1.38–1.87) 199 (14.9%) 2.05 (1.66–2.54)
Prescriber one-off ICS
General practitioner 6,504 (14.1%) 1.0 4,059 (12.5%) 1.0
Specialist 184 ( 5.2%) 0.34 (0.29–0.39) 134 (5.7%) 0.42 (0.35–0.50)
Not speciﬁed 44 (13.6% 0.96 (0.70–1.32) 17 (13.1%) 1.05 (0.63–1.75)
High-dosage treatment with oral corticosteroids (HDT) 12 months prior
No HDT 6,057 (12.7%) 1.0 3,738 (11.3%) 1.0
Well at least one HDT 678 (28.2%) 2.69 (2.45–2.95) 472 (25.0%) 2.70 (2.42–3.01)
Degree of urbanisation of pharmacy locationd
Highest 1,470 (15.5%) 1.0 936 (13.2%) 1.0
High 2,118 (13.7%) 0.87 (0.81–0.93) 1,292 (11.9%) 0.89 (0.81–0.97)
Moderate 1,380 (12.7%) 0.80 (0.73–0.86) 883 (11.6%) 0.87 (0.79–0.96)
Low 1,286 (12.3%) 0.76 (0.70–0.83) 814 (11.8%) 0.88 (0.80–0.97)
Lowest 481 (12.9%) 0.81 (0.72–0.90) 285 (12.2%) 0.92 (0.80–1.06)
Months one-off ICS dispensing in 2011
January 737 (16.8%) 1.0 411 (16.3%) 1.0
February 537 (15.2%) 0.89 (0.79–1.00) 373 (15.9%) 0.97 (0.83–1.13)
March 646 (15.8%) 0.93 (0.83–1.04) 418 (14.5%) 0.88 (0.76–1.02)
April 558 (14.0%) 0.81 (0.72–0.91) 360 ( 9.2%) 0.52 (0.45–0.61)
May 412 (12.5%) 0.71 (0.62–0.81) 271 (9.9%) 0.56 (0.48–0.67)
June 348 (11.8%) 0.66 (0.58–0.79) 251 (10.9%) 0.63 (0.53–0.74)
July 344 (12.2%) 0.69 (0.60–0.79) 198 (10.1%) 0.58 (0.48–0.69)
August 299 (10.1%) 0.55 (0.48–0.64) 228 (11.4%) 0.66 (0.56–0.77)
September 492 (12.7%) 0.72 (0.64–0.81) 305 (11.8%) 0.69 (0.59–0.81)
October 635 (13.7%) 0.79 (0.70–0.88) 365 (12.7%) 0.75 (0.64–0.87)
November 793 (12.6%) 0.71 (0.64–0.80) 468 (11.5%) 0.67 (0.58–0.77)
December 934 (13.1%) 0.75 (0.67–0.83) 562 (12.2%) 0.71 (0.62–0.81)
Abbreviations: CI, conﬁdence interval; ICS, inhaled corticosteroid.
aBased on data from 1,725 (89%) Dutch community pharmacies.
bLogistic univariate regression analysis, statistically signiﬁcant point estimates are shown in bold.
cAge groups are chosen according to cutoff points within the Dutch guidelines for general practitioners.
dAccording to the classiﬁcation of the Dutch Agency of statistics.
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the Dutch GP guidelines for asthma and COPD.12,13 The direct costs of the
dispensed one-off ICS medication without the pharmacy dispensing fee
were calculated using the ofﬁcial listing prices of the ICS medications in
2011. Total direct costs for one-off ICS medication for the whole country
were calculated by extrapolating the information of the number of
pharmacies with sufﬁcient data to all Dutch community pharmacies.
P values below 0.05 were considered to be statistically signiﬁcant. Data
were analysed with PASW statistics 18.0 (IBM, Chicago, IL, USA).
RESULTS
Study sample
Data were available from 1,725 (89%) Dutch community
pharmacies. In 2011, these pharmacies had dispensed at least
one prescription of an ICS (either alone or in single-inhaler
combination with a long-acting betamimetic drug) to 845,068
patients. We identiﬁed 84,821 patients (10.0%) who had received
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Figure 2. (a) Proportion of individuals with co-dispensing of oral antibiotics within one-off inhaled corticosteroids (ICS) users during 2011 by
month for age-categories among patients without antiallergics from 2010 to 2012 (based on data from 1,725 (89%) Dutch community
pharmacies). (b) Proportion of individuals with co-dispensing of oral antibiotics within one-off ICS during 2011 dispensings by month for
age-categories among patients with antiallergics from 2010 to 2012.
0.0
10.0
20.0
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Figure 3. Time lag of co-dispensing of one-off inhaled corticosteroids (ICS) and oral antibiotics in 2011 (based on data from 1,725 (89%) Dutch
community pharmacies).
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only one ICS prescription and no other respiratory medication
during the 12 months before or after this dispensing date
(‘one-off’ ICS, Figure 1). Of the 84,821 one-off ICS users, 59% were
without and 41% were with earlier use of antiallergic drugs.
Association between antibiotics and one-off ICS dispensing
In the univariate logistic regression model, concomitant use of
antibiotics increased the odds of receiving a one-off ICS
dispensing by nearly ﬁve and a half times (OR 5.47, 95%
conﬁdence interval 5.34–5.61). The OR from the multivariate
model was lower (OR 4.30, 95% conﬁdence interval 4.19–4.42) but
still substantial.
Patient characteristics within users of one-off ICS with antibiotics
In the group of patients with one-off ICS dispensings, 10,945
patients (12.9% of the one-off ICS users and 1.3% of all ICS users)
were co-dispensed oral antibiotics. Co-dispensing of oral anti-
biotics among one-off ICS users was slightly higher in the group
without antiallergics (n= 6,735, 13.5% of one-off ICS users)
compared with the group with antiallergics (n= 4,210, 12.1%,
Table 1). Compared with the age category of 7–16 years, all other
age categories had a signiﬁcantly higher risk for co-medication of
an antibiotic in combination with one-off ICS, which was more
than twofold increased in the group of patients aged 65 years or
older who were also using antiallergics. One-off ICS in combina-
tion with antibiotics was prescribed by GPs in 96.5% of cases.
Earlier high-dose treatment with oral corticosteroids (HDTs)
increased the risk for concomitant antibiotics in one-off ICS use
in both strata by 2.7-fold (OR for the combined strata 2.68, 95%
conﬁdence interval 2.50–2.88) compared with no earlier HDT use.
Furthermore, the combination of one-off ICS and antibiotics was
signiﬁcantly lower in pharmacy regions with a lesser degree of
urbanity compared with the highest degree of urbanisation in
pharmacy locations, varying between 11 and 24%. Co-dispensing
of antibiotics in one-off ICS users was overall the highest in
January and signiﬁcantly decreased in all months from April to
December, varying between 10 and 45%.
Variation of co-dispensed antibiotics in season and age categories
Concomitant use of one-off ICS and oral antibiotics occurred
throughout the year in all age categories (Figures 2a and b). All
patterns showed a slight increase in one-off ICS dispensing with
oral antibiotics during the winter months, that was most
pronounced for the age category of 80 years and older that also
used antiallergics (Figure 2b). Overall, 67% of co-dispensing of
one-off ICS and antibiotics occurred on the same day (Figure 3).
The remaining antibiotic co-dispensing was distributed as 23%
during the week after the ICS dispensing and 10% during the
week before. The majority (69.7%) of one-off ICS dispensings with
oral antibiotics were a combination of ICS and LABA (Table 2).
Direct costs of one-off ICS dispensings for respiratory infections
The total annual cost for one-off ICS dispensings in combination
with antibiotics for the 1,725 pharmacies was €490,885 annually,
equivalent to €550,000 annually extrapolated to dispensings from
all 1,950 Dutch community pharmacies. These costs exclude the
dispensing fee, costs for inhalation aids and the costs of the
antibiotic itself.
DISCUSSION
Main ﬁndings
In the Netherlands, the percentages for potentially inappropriate
management of respiratory infections in patients without chronic
airways disease were 13% of one-off ICS dispensing and 1.3% of allT
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ICS dispensings, considerably lower than previous ﬁndings from
Australia, reported as 44% of concomitantly dispensed oral
antibiotics among one-off ICS dispensings and 7.3% of all ICS
prescriptions.20 Nevertheless, in the Netherlands about half a
million Euro of direct costs was involved by this type of
inappropriate ICS prescribing. Furthermore, GPs were almost fully
responsible for combined prescribing of one-off ICS and oral
antibiotics. This may be due to some uncertainty in diagnosing
respiratory conditions. Another possibility is that ICS were used for
treatment of cough27 and a randomised controlled trail concluded
that ICS might be effective in reducing cough in non-smoking
adults.28 However, evidence from a systematic review was
inconclusive and ICS use for cough is not advised in current
guidelines.29 Patients’ age, prior HDT use and calendar month of
ICS dispensing were variables available in our database that
explained some of the one-off ICS dispensing, but there may be
other factors relevant that were not covered by our data, such as
smoking.
Strengths and limitations of this study
A strength of our study was that we could use dispensing data
from the majority of Dutch community pharmacies. Respiratory
medication and antibiotics were fully reimbursed and only
available by prescription so that the medication of interest was
completely covered by our database. By this, one-off ICS use in
combination with antibiotics could be mapped for the whole
country, together with related costs. A limitation was that we did
not possess information regarding dispensings from hospital
pharmacies. However, as hospital pharmacies in the Netherlands
only dispense drugs used during hospital stay, this is not likely to
bias our results. In order to avoid false positives, we used a quite
speciﬁc deﬁnition for one-off ICS use as only one ICS prescription
during 24 months. Thus, our results did not include patients with
co-dispensings of oral antibiotics and an allergic disposition who
used ICS more than once over 2 years. Consequently, our ﬁndings
might be too conservative for inappropriate ICS use in respiratory
infections. A limitation of our data was that information on
diagnoses for antibiotic therapy was not available. Therefore, we
only included short-course antibiotic therapy between 7 and
15 days, according to the Dutch GP recommendations of antibiotic
drug use for respiratory infections.26 The assumption that one-off
ICS were used for treatment of respiratory infections was assured
by the fact that two-thirds of the co-dispensation of ICS and
antibiotics occurred on the same day. Furthermore, concomitant
antibiotic use increased the likelihood of one-off ICS prescribing
within ICS users by more than 4 times. The estimated costs for
one-off ICS dispensings were limited to direct costs by the ofﬁcial
listing price of the ICS medication in 2011, which were available in
the database used. Other related costs to be considered are
pharmacy dispensing fees and costs for training on use of
inhalation medication and inhalation aids, but information on
these determinants was not covered by our data.
Interpretation of ﬁndings in relation to previously published work
Our considerably lower ﬁndings compared with those from
Australia may be partly due to the more speciﬁc deﬁnition of
one-off ICS use in our study with no use of other respiratory
medication 12 months before or after, whereas Poulos et al.20
used a period of 6 months. However, this difference only accounts
for numbers of one-off ICS dispensings within all ICS users and not
the percentage of antibiotic co-medication within this group. By
our more stringent deﬁnition for one-off ICS use, concomitant use
of other respiratory medication from earlier dispensings should be
excluded and consequently the chance of false-positive labelling
for one-off ICS use was diminished. Our ﬁndings are not likely to
be explained by the shopping behaviour of ICS users, as Dutch
patients predominantly visit one community pharmacy30 and we
additionally excluded drop-in patients as those who received only
one dispensing within 2 years. Furthermore, our results are
unlikely to be due to poor adherence to ICS, as ICS in asthma as
well as COPD guidelines are at least a second step in inhalation
treatment, and consequently any other respiratory medication
should have been detected within the year before or after the
one-off ICS dispensing.12–14 Analogous with the results of Poulos
et al.,20 we observed the highest incidences of co-dispensing
during the late winter months. This pattern did not differ for
earlier use of antiallergic drugs.
Implications for future research, policy and practice
The result that 10% of ICS users only received one ICS dispensing
without any other respiratory medication within the prior and
posterior year suggests that potentially inappropriate ICS use
might be higher than one-off ICS dispensings in combination with
antibiotics, on which our study focussed. Further research is
needed to elucidate clinical considerations for ICS prescribing in
clinical practice in order to assess and improve the degree of
implementation of GP guidelines in primary care.
Conclusions
The rate of one-off ICS dispensing in combination with oral
antibiotics in the Netherlands was 13% within one-off ICS
dispensings, which was considerably lower than the 44% reported
from Australia. Nevertheless, there is room for improvement.
About half a million Euro of direct costs could be saved annually
by improving this type of inappropriate ICS prescribing.
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